Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2024 15:18 ET | Source: National Health Regulatory Authority

Bahrain Oncology Centre Amongst the First in the World to Offer Ground-breaking Sickle Cell and Transfusion Dependent Thalassemia Gene Therapy

MUHARRAQ, Bahrain, May 22, 2024 (GLOBE NEWSWIRE) -- The Bahrain Oncology Centre (BOC) has achieved a significant milestone, becoming amongst the first centres in the World to offer the...
April 21, 2022 15:22 ET | Source: Intellijoint Surgical

Grand River Hospital adopts Intellijoint HIP to study patient and health system benefits through $1 million provincial investment

Kitchener, Ontario, April 21, 2022 (GLOBE NEWSWIRE) -- The adoption of novel medical technologies in Canada, especially those not supported by available funding models, is extremely challenging....
January 19, 2021 09:00 ET | Source: Isracann Biosciences Inc.

Isracann Well Positioned for Israel’s Cannabis Sector Growth in 2021

VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on...
October 16, 2018 09:00 ET | Source: AXIM BIOTECHNOLOGIES, INC

Axim® Biotechnologies Earns GMP License From Dutch Ministry of Health to Produce Cannabinoid-Based Pharmaceutical Products

New License Allows Leading Cannabinoid Biopharmaceutical Company to Advance Production of Clinical Trial Products NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM®...
September 23, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...